Phase IIMitochondrial Peptide
Compound 61417
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061417
Risk Class
MODERATE
Last Audit
Jan 29, 2108
Research Abstract
Mitochondrial Peptide candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61417 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061417 with updates logged 2108-01-29.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61417Mitochondrial Peptide Program 61417
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061417
- [2] Operations Pulse • Mitochondrial Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61417